News & Analysis on Clinical Trial Services & Contract Research And Development
TriSalus, Diane Parks, Yongxin Han
By Maggie Lynch
- Last updated on
The life sciences company focused on drug delivery technology for oncology treatments appointed two new members to its board of directors.
Diane Parks will join the board and bring her 30 years of experience in the pharmaceutical industry with her. Parks has held executive roles at Pharamcyclics, Amgen, and Genentech. Most recently she served as the SVP of marketing at Kite Pharma and was credited with leading the launch of the second-ever approved chimeric antigen receptor (CAR)-T therapy, Yescarta.
Yongxin Han, co-founder and general manager of Chemizon and Centaurus BioPharma, will also join the board of directors. In his 20 years in the pharmaceutical industry, he has worked on more than 14 investigational new drug applications for oncology treatments.
Mats Wahlström, TriSalus chairman, said, “We’re honored to add the depth of experience in oncology and drug delivery technology with the appointment of Diane and Yongxin.”